8,994 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Purchased by ST Germain D J Co. Inc.

Key Points

• ST Germain D J Co. Inc. acquired 8,994 shares of Alnylam Pharmaceuticals worth approximately $2.93 million during the 2nd quarter, reflecting institutional interest in the biopharmaceutical company.
• Recent research reports from analysts have raised price targets for Alnylam Pharmaceuticals significantly, with Needham & Company setting a target of $478 and Bank of America increasing it to $520, both giving a "buy" rating.
• Alnylam Pharmaceuticals reported a quarterly EPS of $0.32, exceeding expectations, along with a revenue increase of 17.3% year-over-year to $773.69 million, highlighting the company's growth potential.

ST Germain D J Co. Inc. acquired a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 8,994 shares of the biopharmaceutical company's stock, valued at approximately $2,933,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Vanguard Group Inc. lifted its position in shares of Alnylam Pharmaceuticals by 2.5% during the 1st quarter. Vanguard Group Inc. now owns 13,056,605 shares of the biopharmaceutical company's stock valued at $3,525,544,000 after buying an additional 323,206 shares in the last quarter. Allspring Global Investments Holdings LLC acquired a new position in shares of Alnylam Pharmaceuticals during the first quarter valued at approximately $69,292,000. Adage Capital Partners GP L.L.C. raised its stake in Alnylam Pharmaceuticals by 203.2% in the 1st quarter. Adage Capital Partners GP L.L.C. now owns 282,184 shares of the biopharmaceutical company's stock valued at $76,195,000 after purchasing an additional 189,128 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in shares of Alnylam Pharmaceuticals by 5.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,505,168 shares of the biopharmaceutical company's stock worth $946,466,000 after buying an additional 185,783 shares in the last quarter. Finally, SCS Capital Management LLC purchased a new position in Alnylam Pharmaceuticals in the 1st quarter worth approximately $46,194,000. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. Needham & Company LLC raised their price objective on shares of Alnylam Pharmaceuticals from $377.00 to $478.00 and gave the stock a "buy" rating in a research report on Thursday, July 31st. Wolfe Research upgraded Alnylam Pharmaceuticals from an "underperform" rating to a "peer perform" rating in a report on Monday, August 4th. Bank of America boosted their price target on shares of Alnylam Pharmaceuticals from $453.00 to $520.00 and gave the stock a "buy" rating in a research note on Wednesday, September 17th. Citigroup increased their price target on Alnylam Pharmaceuticals from $527.00 to $583.00 and gave the company a "buy" rating in a research report on Tuesday, September 2nd. Finally, Truist Financial initiated coverage on Alnylam Pharmaceuticals in a research report on Monday, July 21st. They set a "buy" rating and a $385.00 price objective for the company. Twenty-four equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, Alnylam Pharmaceuticals presently has an average rating of "Moderate Buy" and an average price target of $439.58.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, EVP Pushkal Garg sold 1,455 shares of the business's stock in a transaction that occurred on Tuesday, August 19th. The stock was sold at an average price of $458.41, for a total value of $666,986.55. Following the completion of the sale, the executive vice president owned 20,221 shares in the company, valued at approximately $9,269,508.61. The trade was a 6.71% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Colleen F. Reitan sold 18,000 shares of the stock in a transaction that occurred on Tuesday, September 9th. The shares were sold at an average price of $467.60, for a total value of $8,416,800.00. Following the completion of the sale, the director directly owned 775 shares of the company's stock, valued at $362,390. The trade was a 95.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 75,594 shares of company stock worth $33,968,256. Corporate insiders own 1.50% of the company's stock.

Alnylam Pharmaceuticals Trading Down 1.9%

Shares of Alnylam Pharmaceuticals stock opened at $449.58 on Friday. The company has a current ratio of 2.80, a quick ratio of 2.75 and a debt-to-equity ratio of 4.10. The company has a fifty day simple moving average of $425.99 and a 200-day simple moving average of $330.03. The stock has a market cap of $58.93 billion, a price-to-earnings ratio of -182.02 and a beta of 0.32. Alnylam Pharmaceuticals, Inc. has a 12-month low of $205.87 and a 12-month high of $484.21.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share for the quarter, beating analysts' consensus estimates of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The firm had revenue of $773.69 million during the quarter, compared to analysts' expectations of $633.54 million. During the same period in the previous year, the company earned ($0.13) earnings per share. Alnylam Pharmaceuticals's quarterly revenue was up 17.3% compared to the same quarter last year. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. On average, equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.